Argos Therapeutics (ARGS) Misses Q2 EPS by 5c

Argos Therapeutics (NASDAQ: ARGS) reported Q2 EPS of ($0.48), $0.05 worse than the analyst estimate of ($0.43). Revenue for the quarter came in at $488.64 thousand versus the consensus estimate of $200 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• BitFuFu Inc. (FUFU) Misses Q2 EPS by 13c